The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 13 of the 38 sources its claims cite were checked for support.
Brain-targeted drug delivery by manipulating protein corona functions
Open accessAbstract
Abstract Protein corona presents a major obstacle to bench-to-bedside translation of targeted drug delivery systems, severely affecting targeting yields and directing unfavorable biodistribution. Corona-mediated targeting provides a new impetus for specific drug delivery by precisely manipulating interaction modes of functional plasma proteins on nano-surface. Here bio-inspired liposomes (SP-sLip) were developed by modifying liposomal surface with a short nontoxic peptide derived from Aβ 1-42 that specifically interacts with the lipid-binding domain of exchangeable apolipoproteins. SP-sLip absorb plasma apolipoproteins A1, E and J, consequently exposing receptor-binding domain of apolipoproteins to achieve brain-targeted delivery. Doxorubicin loaded SP-sLip (SP-sLip/DOX) show significant enhancement of brain distribution and anti-brain cancer effect in comparison to doxorubicin loaded plain liposomes. SP-sLip preserve functions of the absorbed human plasma ApoE, and the corona-mediated targeting strategy works in SP modified PLGA nanoparticles. The present study may pave a new avenue to facilitate clinical translation of targeted drug delivery systems.
Overview
CoChat Summary
TL;DR
The paper reports a corona-mediated brain-targeting strategy in which a short Aβ-derived peptide on liposomes recruits exchangeable apolipoproteins and exposes their receptor-binding domains for BBB transport. In mouse models, the resulting SP-sLip improved brain accumulation and strengthened doxorubicin’s anti-glioma/anti-medulloblastoma efficacy compared with plain liposomes.
Key findings
- SP-sLip rapidly absorbed apolipoproteins ApoA1, ApoE, and ApoJ; in mouse plasma, the corona showed plateaued binding within 5–30 min, with ApoE binding measured at 2.8 μg ApoE per mg lipid for SP-sLip versus 1.6 μg ApoE per mg lipid for sLip.
- In vivo, SP-sLip showed higher apolipoprotein content in its protein corona than sLip for all three proteins after intravenous injection, indicating specific absorption occurred in circulation.
- After plasma preincubation, SP-sLip retained ApoE functionality: it bound 8.4-fold more radiolabeled rhLRP1 than sLip, and SP-sLip enhanced uptake by bEnd.3 cells only when ApoE or mouse plasma was present.
- Brain delivery and therapy improved substantially: SP-sLip/DOX produced 14.5-fold higher brain doxorubicin distribution than sLip/DOX in healthy BALB/c mice at 4 h (0.93% ID/g vs 0.061% ID/g), increased glioma-region distribution by 45-fold, prolonged median survival in intracranial U87-bearing mice to 50 days versus 33 days with sLip/DOX, and in D425-bearing mice to 29 days versus 25 days with sLip/DOX.
Methods
- Bio-inspired PEGylated liposomes were prepared with or without a short Aβ-derived peptide (SP), and doxorubicin-loaded formulations were made by ammonium sulfate gradient loading; SP was also tested on PLGA nanoparticles.
- The study used in vitro ApoE binding assays, plasma protein corona isolation, SDS-PAGE/nano-LC-MS/MS, ELISA, Western blotting, cellular uptake in bEnd.3 cells, and in vivo biodistribution/pharmacodynamics in BALB/c mice, SD rats, and nude mice bearing intracranial U87 or D425 tumors.
- Main analysis compared corona composition, receptor binding to rhLRP1, brain distribution, survival, and toxicity between SP-sLip, sLip, free DOX, and saline controls using t-tests and log-rank tests.
Limitations
- The paper does not report a full mechanistic proof that the enhanced brain targeting is exclusively due to ApoE/LRP1, and it notes that intracranial tumor accumulation may be at least partially attributed to LRP1 mediation.
- It does not state long-term safety, full pharmacology, or clinical outcomes; the evidence is preclinical in mice and rats.
- The text makes evident that the survival studies use small animal groups (for example, n = 12–13 for U87 and n = 7–9 for D425), which limits precision; this is not stated as a limitation by the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
7 Valid · 1 Not valid · 8 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aβ peptides have been reported to directly bind LRP1 for clearance37,38.”
§ Brain-targeted drug delivery by manipulating protein corona functions > Results > SP-sLip preserve functions of absorbed apolipoproteins
What the sources say
- Supportedcites [37] Deane, R. et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333–344 (2004). source
The Abstract reports direct binding of Aβ40 to LRP (LRP1) and LRP-mediated transport across the blood–brain barrier. The Results report LRP-dependent binding and clearance of Aβ isoforms by brain capillaries, with differing affinities across isoforms. (LLM, conf=0.94)
- Supportedcites [38] Storck, S. E. et al. Endothelial LRP1 transports amyloid-beta(1-42) across the blood-brain barrier. J. Clin. Investig. 126, 123–136 (2016). source
The Discussion states that LRP1 has binding affinity for Aβ1-40 and Aβ1-42 and that both variants are cleared by LRP1. The section on differential binding affinity likewise describes LRP1 binding to these peptides. The supplied passages do not include page numbers. (LLM, conf=0.90)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Protein corona presents a major obstacle to bench-to-bedside translation of targeted drug delivery systems, severely affecting targeting yields and directing unfavorable biodistribution.”
- Also stated in: § Introduction · hedged
“After entry into blood stream, the formed protein corona on the surface of TDDS determines what is seen by living organisms, may severely affecting the targeting yields and inducing unfavorable biodistribution8–12. Protein corona presents a major obstacle to the bench-to-bedside translation of TDDS.”
§ Brain-targeted drug delivery by manipulating protein corona functions > Abstract
What the sources say
- Not checked — no full text of the sourcecites [8] Caracciolo, G., Farokhzad, O. C. & Mahmoudi, M. Biological identity of nanoparticles in vivo: clinical implications of the protein corona. Trends Biotechnol. 35, 257–264 (2017). source
- Partly supportedcites [9] Barbero, F. et al. Formation of the protein corona: the interface between nanoparticles and the immune system. Semin. Immunol. 34, 52–60 (2017). sourceExperimental — accuracy not yet measured
Our copy supports only the general level: the Abstract states the protein corona 'provides the biological identity to the nanoparticle that the immune system will detect' and that this 'has important implications on immune safety, biocompatibility and the use of nanoparticles in medicine', and the section 'The interactions of nanoparticles and the innate immune system' says corona formation gives NPs 'a new biological identity ... ultimately determining their physiological response and toxicity', with NP-protein interactions influencing 'reactivity, bioavailability and pharmacokinetics'. What the source does not state is the specific attribution in the claim: that the corona is a major obstacle to bench-to-bedside translation of targeted drug delivery, that it severely reduces targeting yields, or that it directs unfavourable biodistribution — no passage in our copy (searched: clinical translation, targeting ligands/efficiency, biodistribution, drug delivery challenges) makes that argument, and the same section also reports favourable corona effects (serum proteins stabilising NPs against aggregation, crowding helping maintain native protein structure). So the direction-of-effect framing and the targeting-yield/biodistribution specifics are not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [10] Chen, F. et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat. Nanotechnol. 12, 387–393 (2017). sourceExperimental — accuracy not yet measured
The introductory passage labeled Abstract (page unavailable) says the protein coat may affect nanoparticle targeting, pharmacokinetics and biodistribution; the paper also reports complement-mediated immune uptake. It does not establish that the corona severely reduces targeting yields, causes unfavorable biodistribution, or is a major obstacle to clinical translation. (LLM, conf=0.86)
- Partly supportedcites [11] Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 137–143 (2013). sourceExperimental — accuracy not yet measured
The paper reports that a protein corona can shield transferrin on nanoparticles and eliminate targeting specificity in a biological environment (main text; page not supplied). Its conclusion says this failure may allow accumulation in unintended cells, but it does not demonstrate unfavorable biodistribution or establish the extent of an obstacle to clinical translation. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [12] Shen, L. et al. Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses. J. Allergy Clin. Immunol., https://doi.org/10.1016/j.jaci.2017.08.049 (2018). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Exchangeable apolipoproteins (such as ApoA, C, and E) that can direct the transport of lipids through lymphatic and circulatory systems have been found in protein coronas formed on the surface of a variety of drug delivery systems15–17.”
§ Brain-targeted drug delivery by manipulating protein corona functions > Introduction
What the sources say
- Partly supportedcites [15] Cedervall, T. et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050–2055 (2007). sourceExperimental — accuracy not yet measured
Our copy supports apolipoproteins in nanoparticle coronas only in general and for ApoA-I specifically: the Introduction states that 'other proteins observed with several particle types in these centrifugation assays are immunoglobulins, apolipoproteins and alpha-1-antitrypsin', and the centrifugation/gel-filtration sections identify the 28-kDa band as apolipoprotein A-I, preferentially bound to the copolymer particles. No passage in our copy names apolipoprotein C or apolipoprotein E (searched: 'apolipoprotein C/apoE', 'apoA apoE corona'), so the 'such as ApoA, C, and E' enumeration is not attributable to this source. The particles this paper actually characterises are NIPAM/BAM copolymer (and thiol-linked gold) model nanoparticles in plasma, not 'a variety of drug delivery systems' — that breadth comes only from its cited centrifugation literature (refs 5-18). Finally, describing these apolipoproteins as 'exchangeable' runs against the paper's emphasis: it reports ApoA-I coelutes with particles over ~2 h, i.e. a much slower exchange rate than albumin and fibrinogen, and displaces them at longer times. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [16] Casals, E., Pfaller, T., Duschl, A., Oostingh, G. J. & Puntes, V. Time evolution of the nanoparticle protein corona. ACS Nano 4, 3623–3632 (2010). source
- Partly supportedcites [17] Bertrand, N. et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat. Commun. 8, 777 (2017). sourceExperimental — accuracy not yet measured
The Results (‘In vivo protein corona’; page unavailable) report apolipoproteins in coronas on metal, lipid, and polymer nanoparticles, and the study identifies ApoE on its polymeric nanoparticles. The passages do not specifically identify ApoA or ApoC in those coronas, so those examples are not established by this source. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Unfortunately, plasma protein absorption on liposomal surface is inevitable even in the presence of PEG8,48,49.”
§ Brain-targeted drug delivery by manipulating protein corona functions > Discussion
What the sources say
- Not checked — no full text of the sourcecites [8] Caracciolo, G., Farokhzad, O. C. & Mahmoudi, M. Biological identity of nanoparticles in vivo: clinical implications of the protein corona. Trends Biotechnol. 35, 257–264 (2017). source
- Partly supportedcites [48] Al-Ahmady, Z. S., Hadjidemetriou, M., Gubbins, J. & Kostarelos, K. Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes. J. Control. Release. 276, 157–167 (2018). sourceExperimental — accuracy not yet measured
Our copy of Al-Ahmady et al. (2018) is the institutional repository record: title/metadata plus the Abstract only — searches for 'PEG', 'PEGylated', 'stealth coating' and introduction-level discussion returned no body-text passages. The Abstract does support the general point that plasma proteins adsorb onto the liposome surface in vivo ('the actual adsorption of proteins onto the surface of TSL after their in vivo administration, also known as "protein corona"', and recovery of 'protein corona coated TSL' from the blood circulation of CD-1 mice). However, nothing in our copy addresses the qualifier 'even in the presence of PEG' — no PEGylated formulation or PEG-resistance claim appears — so that part of the citing sentence is unsupported by this source. (LLM, conf=0.65)
- Partly supportedcites [49] Bigdeli, A. et al. Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano 10, 3723–3737 (2016). sourceExperimental — accuracy not yet measured
The Abstract of our copy states the general half of the claim: liposomes 'upon entering the biological media... are also immediately surrounded by high levels of proteins... forming a rich protein corona', and Results/Table 1 show measurable protein bound (4-11 µg/µL) for all 17 formulations after 1 h with human plasma. However, the PEG qualifier is not made anywhere in our copy: PEG appears only as a lipid reagent (DOPE-PEG-1K/2K/5K, Samples Preparation) and via a cited reference on PEG chain length (ref. 9, Pozzi et al., Nanoscale 2014), and the paper's own discussion attributes lower adsorption to neutral rather than PEGylated surfaces ('liposomes with charged surfaces tend to adsorb more proteins than those with neutral surfaces'). So 'even in the presence of PEG' is not supported by this source. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Some of those exchangeable apolipoproteins (ApoA1 and ApoE) can cross the blood-brain barrier (BBB) via receptor-mediated transcytosis18–21”
§ Brain-targeted drug delivery by manipulating protein corona functions > Introduction
What the sources say
- Not checked — no full text of the sourcecites [18] Rip, J., Schenk, G. J. & de Boer, A. G. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv. 6, 227–237 (2009). source
- Partly supportedcites [19] Wang, D. et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc. Natl Acad. Sci. USA 110, 2999–3004 (2013). sourceExperimental — accuracy not yet measured
The Intro (p.1) states that LDLR-superfamily proteins (LRP1, VLDLR) 'are abundantly expressed on BBB and can bind apolipoproteins to facilitate their transcytosis across the BBB', and the Discussion frames 'endogenous receptor-mediated transcytosis for the entrance of proteins such as transferrin, insulin, or apolipoproteins' as a route for selective BBB transport; the apoE arm of the claim is further carried by the paper's own demonstration that an apoE receptor-binding domain fused to IDUA is transcytosed (in vitro BBB model, LRP1-mediated via RAP inhibition). However, our copy says nothing about apolipoprotein A-I crossing the BBB — apoA-I appears only inside the title of cited ref. 15 (Kreuter et al., apolipoprotein A-I/B-100-conjugated albumin nanoparticles), which the body text describes as an apoE-nanoparticle/LDLRf transcytosis study — and the category 'exchangeable apolipoproteins' is never used. So the ApoA1 and 'exchangeable' qualifiers attributed here are not supported by this source. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [20] Pflanzner, T. et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol. Aging 32, 2323 e2321–2311 (2011). source
- Not checked — no full text of the sourcecites [21] Demeule, M. et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106, 1534–1544 (2008). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
39 more claims
Create a free account to see all 69 claims and to verify the 3 references still open.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Significant enhancement of the brain distribution of DOX-loaded liposomes as well as higher anti-tumor efficacy were found.”
From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [253]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“SP-sLip/DOX (ID% g−1 = 0.93%) treated mice had 14.5-fold higher brain doxorubicin distribution than sLip/Dox (ID% g−1 = 0.061%) treated mice.”
§ Brain-targeted drug delivery by manipulating protein corona functions > Results > SP-sLip can penetrate BBB and target brain cancers
Reported 14.5 · recomputed 15.245902
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“253 Quan et al. developed transferrin receptor aptamer-functionalized liposomes to deliver acetylcholinesterase reactivator in brain (Fig.”
BackgroundThe protein corona from nanomedicine to environmental science
Mahmoudi, M., Landry, M. P., Moore, A., & Coreas, R. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00552-2 · Cited by 625
Qiu, M., Tang, Y., Chen, J., Muriph, R., Ye, Z., Huang, C., Evans, J., Henske, E. P., & Xu, Q. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116271119 · Cited by 504
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 488
Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., & Agostini, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00166 · Cited by 390
Metadata
- Authors
- Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., & Zhan, C.
- Affiliations
- Fudan University (CN)
- Corresponding author
- Zhan, Changyou
- Venue
- Nature Communications
- Published
- 2019-08-08
- Volume
- 10
- Issue
- 1
- Pages
- 3561-3561
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6687821
- OpenAlex
- W2968488780
- Cited by
- 334
- References
- 62
- Citations by year
- 2026: 30 · 2025: 59 · 2024: 61 · 2023: 56 · 2022: 49 · 2021: 38 · 2020: 36 · 2019: 4
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- China Postdoctoral Science Foundation (2017M610229)
- Shanghai Education Development Foundation (2017-01-07-00-07-E00052)
- Shanghai Municipal Health Bureau (2018BR04)
- Natural Science Foundation of Shanghai (18ZR1404800)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- protein corona, brain drug delivery, amyloid-beta, apolipoprotein E, apolipoprotein A-I, clusterin, plasma protein binding, doxorubicin, PLGA nanoparticles, brain cancer, tissue distribution
- MeSH terms
- Protein Corona, Animals, Apolipoproteins E, Brain, Brain Neoplasms, Doxorubicin, Humans, Liposomes, Male, Peptide Fragments, Tissue Distribution, Amyloid beta-Peptides, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Rats, Nanoparticles, Protein Interaction Domains and Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain-targeted drug delivery by manipulating protein corona functions. https://app.cochat.ai/papers/10.1038/s41467-019-11593-z
- The paper
- Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., & Zhan, C. (2019). Brain-targeted drug delivery by manipulating protein corona functions. Nature Communications. https://doi.org/10.1038/s41467-019-11593-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.